CymaBay Therapeutics to Participate in Upcoming Investor Conferences in October
NEWARK, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in upcoming investor conferences, including the 2018 Cantor Global Healthcare Conference, the LEERINK Partners Roundtable Series: Rare Disease & Oncology, and the ROTH Battle of the NASH Thrones Investor Conference.
2018 Cantor Global Healthcare Conference Date: Monday, October 1 Time: 8:55am Eastern Time Location: Intercontinental Barclay New York Hotel Webcast: http://ir.cymabay.com/events LEERINK Partners Roundtable Series: Rare Disease & Oncology Date: Tuesday, October 2 Time: 8:30am Eastern Time Location: Lotte New York Palace Hotel Webcast: http://ir.cymabay.com/events ROTH Battle of the NASH Thrones Investor Conference Date: Wednesday, October 17 Time: Panel discussions and 1-on-1 meetings Location: Park Hyatt New York Hotel
About CymaBay CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist, currently in development for the treatment of patients with primary biliary cholangitis (PBC), an autoimmune liver disease, and with non-alcoholic steatohepatitis (NASH).
For additional information about CymaBay visit www.cymabay.com.
Contact: Hans VitzthumLifeSci Advisors, LLC212-915-2568 Hans@LifeSciAdvisors.com